Navigation Links
Two New U.S. Patents Issued to Dyadic International
Date:4/7/2011

JUPITER, Fla., April 7, 2011 /PRNewswire/ -- Dyadic International, Inc. ("Dyadic") (OTC Pink: DYAI), a global biotechnology company focused on the discovery, development, manufacture and sale of enzyme and protein products for the bioenergy, industrial enzyme and biopharmaceutical industries, announced today that it has been issued U.S. Patent No. 7,906,309 entitled, "Expression-Regulating Sequences and Expression Products in the Field of Filamentous Fungi" and U.S. Patent No. 7,892,812 entitled, "Chrysosporium Cellulase and Methods of Use" by the United States Patent and Trademark Office ("USPTO").

(Logo: http://photos.prnewswire.com/prnh/20091214/DYADICLOGO)

U.S. Patent No. 7,906,309
"Expression-Regulating Sequences and Expression Products in the Field of Filamentous Fungi"

The inventions embodied by this patent are genes and their corresponding enzymes from glycosyl hydrolase family 10 having xylanase activity which are derived from Chysosporium fungal strains. Other related applications claim cellobiohydrolases and glyceraldehyde phosphate dehydrogenases. These enzymes have proven to be effective in breaking down the major component of plant cell walls, commonly known as lignocellulosic biomass, into fermentable C5 sugars which can be used in the production of biofuels and biochemicals.  These genes and enzymes were isolated from Dyadic's patented and proprietary C1 fungus and identified through the genome annotation project conducted by Dyadic in conjunction with Scripps Florida.

Dyadic's President and Chief Executive Officer, Mark Emalfarb, stated, "This patent protects Dyadic's ability to use its C1 technology to make fermentable C5 sugars in addition to the C6 sugars allowed by our previously awarded biofuels patent."

U.S. Patent No. 7,892,812
"Chrysosporium Cellulase and Methods of Use"

The inventions embodied by this patent are industrial uses and novel methods of manufacturing endoglucanases and other groups of neutral or alkaline cellulases that are isolated from Chrysosporium fungal strains. These enzymes work over broader temperature and pH ranges than other commercially available enzymes. Endoglucanases are commercially useful in the processing of cellulose-based materials with applications in the biofuels, biochemicals, beverage, feed, textiles and pulp and paper industries among other potential uses.

These newly issued patents are accessible on the USPTO's website at www.uspto.gov or on Dyadic's website at www.dyadic.com.

These patents are the eighth and ninth U.S. patents issued to Dyadic adding to its portfolio of 74 international patents and more than 33 pending patent applications worldwide which cover various features of Dyadic's proprietary technologies.

About Dyadic

Dyadic International, Inc. is a global biotechnology company that uses its patented and proprietary technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of enzyme and protein products for the bioenergy, industrial enzyme and biopharmaceutical industries.

Dyadic utilizes an integrated technology platform based on its patented and proprietary C1 fungus, which enables the development and large scale manufacture of low cost proteins and enzymes for diverse market opportunities. The C1 Platform Technology can also be used to screen for the discovery of novel genes and proteins. Dyadic actively pursues licensing arrangements and other commercial opportunities to leverage the value of these technologies by providing its partners and collaborators with the benefits of manufacturing and/or utilizing the enzymes which these technologies help produce.

Cautionary Statement for Forward-Looking Statements

Certain statements contained in this press release are forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause Dyadic's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Except as required by law, Dyadic expressly disclaims any intent or obligation to update any forward-looking statements.


'/>"/>
SOURCE Dyadic International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Source Precision Medicine, Inc. d/b/a Source MDx Announces Foundational Patents Will Be Offered for Sale on April 29, 2011
2. Court Rules on First Set of Patents in FENTORA Litigation
3. caprotec bioanalytics Announces Issuance In Europe of All Core Patents of Its CCMS Technology
4. ICAP Ocean Tomo Announces Patents for a New and Safer Method of Treatment of Osteoporosis and Tumor Metastasis Using a Novel Zoledronic Acid Combination
5. Cutting Edge Nanotech Patents for Displays, Lighting, X-ray, Medical Imaging, and Diagnostics Available for Sale by ICAP Ocean Tomo
6. Sensipar® Patents Upheld By District Court
7. COPAN Files New Patents Following the Development of High Nucleic Acid Yield Flocked Swabs
8. Interventional Spine®, Inc. Announces Issuance of Key Patents for the PERPOS® PLS System
9. Microfluidic Systems (MFSI) is Awarded Four New Patents in the Field of Automated Biological Sample Processing and Detection.
10. Volcano Corporation Files Counterclaim Asserting St. Jude Infringes Three Volcano Patents; Answers St. Judes Patent Infringement Claims
11. Amedica® Receives Patents for Innovative Motion-Preserving Total Disc Implant Featuring Silicon Nitride
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... 27, 2017  ImMAGE Biotherapeutics (OTCMKTS: IMMG), an early-stage ... early toxicology and efficacy studies. The company is harnessing ... specific protein, MAGE A, in an effort to find ... After 4 weeks of treatment in transgenic ... little toxicity in a full toxicology report of various ...
(Date:3/27/2017)... March 27, 2017  Sanderling Ventures, portfolio company, ... a division of Johnson & Johnson. Torax manufactures and ... treatment of gastro-esophageal reflux disease (GERD). The LINK ... technology and the procedure is currently available in ... Torax Medical was founded by Sanderling Ventures, Mayo ...
(Date:3/27/2017)... March 27, 2017 BioLineRx Ltd. (NASDAQ/TASE: ... announced today that AGI-134, an immunotherapy for the treatment of ... Ltd., will be featured at the upcoming American Association ... Washington, DC to be held on April 1-5, ... ...
Breaking Medicine Technology:
(Date:3/27/2017)... ... March 27, 2017 , ... Adding to its expanding portfolio ... Medicine and NEJM Journal Watch, announces the release of NEJM Knowledge+ Pediatrics ... panel of pediatricians from leading medical centers. The content was then reviewed and ...
(Date:3/27/2017)... ... March 27, 2017 , ... The Case Management Society of America ... June 30, 2017. CMSA’s membership has elected their upcoming President-Elect, Secretary, Treasurer and ... Advisory position, a new VA Advisory position has also been added to the BOD, ...
(Date:3/27/2017)... ... March 27, 2017 , ... Osteitis ... A type of groin injury, it occurs when the muscles around the pelvis ... in and around the lower torso, as well as accompanying tenderness and weakness. ...
(Date:3/27/2017)... ... March 27, 2017 , ... Advantexe ... announced the launch of a new research study, The Business Readiness Report. The ... execute that strategy, and the actual success of achieving individual and company goals. ...
(Date:3/27/2017)... ... March 27, 2017 , ... Kwalu, ... second year in a row; they are the recipient of the prestigious “Best ... voted on the award at Design Connections 2017. Top A&D professionals from leading ...
Breaking Medicine News(10 mins):